Navigation Links
American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
Date:9/3/2009

NEW YORK and BEIRUT, Sept. 3 /PRNewswire/ -- A medical team at the American University of Beirut Medical Center (AUBMC) has successfully performed the first artificial heart implant in Lebanon, saving the life of a 37-year-old man suffering from terminal heart failure.

Led by two AUB doctors, the six-hour operation, which took place on August 28, 2009, was deemed a success after the patient survived the first critical 72 hours and showed improvements in all his vital signs. The artificial heart implant operation involves the insertion of a left ventricular assist device (LVAD) that assumes the functions of the left ventricle of the heart, the dominant chamber which is responsible for pumping oxygenated blood via the aorta to the rest of the body.

"The operation was a huge success as it was this patient's last chance at life," said Dr. Pierre Sfeir, the AUBMC surgeon who conducted the operation.

"His vital organs are functioning normally and the new device implant is pumping blood properly," added Dr. Hadi Skouri, the AUBMC cardiologist who has been treating the patient and a specialist on heart failure and transplantation.

The LVAD used in this surgery, the Heartmate II, is manufactured by the US medical technology company, Thoratec.

The two AUB doctors were assisted by a multidisciplinary medical team, including a leading expert on LVAD operations, Dr. Latif Arusoglu, a German surgeon, as well as a clinical specialist, both dispatched by Thoratec.

"90 percent of all cardiac failures are the result of left ventricular failure," explained Dr. Skouri. When the left ventricle does not function adequately, there are several treatment options available to physicians, he added. As a first step, these patients are placed on a drug therapy that helps the heart pump blood. If that is not successful, patients might undergo a relatively simple operation that involves inserting a pacemaker or other devices that help improve the heart's pumping function. As a last resort, physicians opt for human heart transplants. Since human heart donors are in short supply, surgeons have previously used the LVAD as a temporary solution, while waiting for a human donor heart.

LVADs have been available to patients since the mid-1990s, but only through an in-hospital procedure. Not all patients are eligible for this expensive and complicated surgery: "If the patient suffers from other serious chronic diseases, we cannot operate," said Dr. Sfeir, who heads the Division of Cardio-thoracic Surgery at AUBMC.

Dr. Samir Alam, who heads the Cardiology Division, stressed that LVADs are a "last-resort treatment." "Although we are very excited to offer this new procedure to our patients, we cannot stress enough the complexity of this surgery and the fact that not all cardiac patients are eligible for this implant," he noted.

"I was facing death when I arrived here," said the 37-year-old father of four who was operated on at AUBMC. "Merely lifting an arm would knock the wind out of me. I could barely breathe. Now, I have a new lease on life." He added: "My family is really, really happy. My dad cannot stop smiling."

About the AUB Medical Center

AUBMC is the private, not-for-profit teaching center of the Faculty of Medicine at the American University of Beirut. It consists of a 420-bed medical center and provides all medical, surgical, pediatrics, obstetrics/gynecological and psychiatric services. The Medical Center offers comprehensive healthcare services, extensive tertiary/quaternary resources, medical, nursing, and paramedical training.

www.aubmc.org.lb

    Contact:
    Ada H. Porter, Director of Communications (USA)
    porter@aub.edu (212) 583-7618
    Ibrahim Khoury, Director of Information and Public Relations (Lebanon)
    ifkhoury@aub.edu.lb 011961350000x2670


'/>"/>
SOURCE American University of Beirut
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
2. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
3. New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform
4. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
5. SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
6. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
7. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
8. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
9. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
10. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
11. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, thought ... After Parker at Stonegate changed ownership, it was time to refresh the carpeting ...
(Date:8/18/2017)... (PRWEB) , ... August 19, 2017 , ... ... Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism ... Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... financial consultations to communities throughout the greater DC region, is inaugurating a “New ... of rescuing local animals and training them to be companions for veterans in ...
Breaking Medicine News(10 mins):